Patients With Hereditary Gastric Cancer Linked to a Family History of Hereditary Breast and Ovarian Cancer (HBOC)

preprint OA: closed
Full text JSON View at publisher

Abstract

_Helicobacter pylori_ (_H. pylori_), a bacteria which chronically infects the stomach of approximately half people in the world, is a risk factor for the development of gastric cancer (GC). However, the detailed mechanism by which _H. pylori_ infection induces GC development remains unclear. Intermittent injection of the _H. pylori_ CagA protein in to its host cell, inhibits the nuclear translocation of BRCA1/BRCA2-the DNA repair proteins involved prominently in breast cancer development. Interestingly, hereditary breast and ovarian cancer syndrome (HBOC) is associated with GC development. Here, we aimed to understand the molecular link between _H. pylori_ infection, _BRCA1/2_ pathogenic variants (PVs), GC and higher incidence of GC in HBOC families. To do so, in this retrospective clinical observation study, we checked the database of Japanese patients undergoing precision treatment using cancer genomic medicine. Indeed, we found a higher incidence of GC in HBOC families having germline pathogenic variants (GPVs) of _BRCA1/2_ (2.95 % vs. 0.78% (in non-HBOC families). Next we, found that 96.1 % _H. pylori_ infected patients received cancer genomic medicine examination for advanced GC, and > 16% advanced GC patients had _gBRCA2_ PVs. Moreover, histological examination of GC tumor tissue showed that gastric mucosa epithelial cells infected with CagA-positive _H. pylori_ strains were lacking in nuclear BRCA1. Further, we found that expressing wildtype BRCA1/2 in the _Gan_ mice (a mouse model of human GC), inhibited GC development. Thus, _gBRAC1/2_ PVs and _H. pylori_ infection synergistically increase the risk of GC development. Our study thus highlights the need for early eradication of _H. pylori _infection in HBOC family members to prevent GC development. Further, it indicates that that poly(ADP-ribose) polymerases (PARPs) inhibitors will be effective in halting development and progression of GCs in HBOC families with _gBRCA1/2_ PVs.
Full text 621 characters · extracted from oa-doi-fallback · click to expand
There is a newer version available for this {{ publicationType }}. View latest version {{ publication.field_name }} {{ publication.subfield_name }} Copyright: © {{ publicationYear }} {{ publication.presentation_authors[0].full_name + (publication.presentation_authors.length > 1 ? ' et al' : '') }}. This is an open access publication distributed under the terms of the CC BY 4.0 License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Check the {{ publicationType | capitalize }} Source for copyright and license information. Listen on

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. This is a recent paper (2024) — citers typically take a year or two to land, and the OpenAlex reference graph may still be filling in.

Source provenance

europepmc
last seen: 2026-05-20T01:45:00.602351+00:00